Nonetheless, our study unearthed noteworthy disparities in SA-AKI grade post-treatment between the two cohorts, with HPA inhibitor utilization correlating with diminished requirements for RRT and reduced hospitalization costs, thus alleviating the financial burden on patients. The gene discussed is HPSE; the disease is acute kidney injury.